Evidence map›Paper›PMID 33203179›Full record

ArticleCells2020

Quick, Coordinated and Authentic Reprogramming of Ribosome Biogenesis during iPSC Reprogramming.

Kejin Hu

Open access · goldAbstract read
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Kejin HuDepartment of Biochemistry and Molecular Genetics, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-3111-4054
University of Alabama at Birmingham · US

Funding

UAB Childhood Cystic Kidney Disease Core Center (UAB-CCKDCC) - Therapeutic Development and Screening ResourceU54DK126087 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI John M Parant · 2020 to 2026
$6.7M
BET Regulation of Mitosis and Pluripotency EstablishmentR01GM127411 · NIGMS · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI HU, KEJIN · 2018 to 2022
$1.6M
NIDDK NIH HHS U54 DK126087NIGMS NIH HHS R01 GM127411
6 · The paper itself

Abstract

Induction of pluripotent stem cells (iPSC) by OCT4 (octamer-binding transcription factor 4), SOX2 (SR box 2), KLF4 (Krüppel-Like Factor 4), and MYC (cellular Myelocytomatosis, c-MYC or MYC) (collectively OSKM) is revolutionary, but very inefficient, slow, and stochastic. It is unknown as to what underlies the potency aspect of the multi-step, multi-pathway, and inefficient iPSC reprogramming. Mesenchymal-to-epithelial (MET) transition is known as the earliest pathway reprogrammed. Using the recently established concepts of reprogramome and reprogramming legitimacy, the author first demonstrated that ribosome biogenesis (RB) is globally enriched in terms of human embryonic stem cells in comparison with fibroblasts, the popular starting cells of pluripotency reprogramming. It is then shown that the RB network was reprogrammed quickly in a coordinated fashion. Human iPSCs also demonstrated a more robust ribosome biogenesis. The quick and global reprogramming of ribosome biogenesis was also observed in an independent fibroblast line from a different donor. This study additionally demonstrated that MET did not initiate substantially at the time of proper RB reprogramming. This quick, coordinated and authentic RB reprogramming to the more robust pluripotent state by the OSKM reprogramming factors dramatically contrasts the overall low efficiency and long latency of iPSC reprogramming, and aligns well with the potency aspect of the inefficient OSKM reprogramming.

Indexed as

Cell DifferentiationCell LineCellular ReprogrammingFibroblastsHomeodomain ProteinsHumansInduced Pluripotent Stem CellsKruppel-Like Factor 4Pluripotent Stem CellsProto-Oncogene Proteins c-mycTranscription FactorsHomeodomain ProteinsKLF4 protein, humanKruppel-Like Factor 4Proto-Oncogene Proteins c-mycTranscription Factorsfibroblastshuman embryonic stem cell (ESC)induced pluripotent stem cell (iPSC)mesenchymal-to-epithelial transition (MET)OCT4/SOX2/KLF4/MYC (OSKM)reprogramming legitimacyreprogramomeribosome biogenesisRNA-seqtranscription profilingtranscriptome

Identifiers

PMID33203179
PMCPMC7697288
OpenAlexW3105918440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.